MBX Biosciences, Inc.
MBX
$10.44
$0.2652.61%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 12.84M | 10.98M | 9.86M | 8.86M | 8.13M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 81.41M | 68.19M | 59.58M | 50.91M | 42.26M |
Operating Income | -81.41M | -68.19M | -59.58M | -50.91M | -42.26M |
Income Before Tax | -73.47M | -61.92M | -55.18M | -47.20M | -38.95M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -73.47 | -61.92 | -55.18 | -47.20 | -38.95 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -73.47M | -61.92M | -55.18M | -47.20M | -38.95M |
EBIT | -81.41M | -68.19M | -59.58M | -50.91M | -42.26M |
EBITDA | -81.14M | -67.95M | -59.35M | -50.72M | -42.09M |
EPS Basic | -16.59 | -26.13 | -33.39 | -40.00 | -35.06 |
Normalized Basic EPS | -10.42 | -16.39 | -21.44 | -25.57 | -22.49 |
EPS Diluted | -16.59 | -26.13 | -33.39 | -40.00 | -35.06 |
Normalized Diluted EPS | -10.42 | -16.39 | -21.44 | -25.57 | -22.49 |
Average Basic Shares Outstanding | 74.58M | 42.37M | 10.12M | 4.68M | 4.42M |
Average Diluted Shares Outstanding | 74.58M | 42.37M | 10.12M | 4.68M | 4.42M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |